GE Healthcare Inc

GE Healthcare CFO William Grogan boosts his stake, exercising stock options to signal strong confidence and long‑term commitment to company growth.

GE HealthCare executives sell shares to meet tax‑withholding on RSUs, yet no major capital change – see the latest Form 4 filing details.

Discover how GE Healthcare’s imaging, visualization, patient‑care, and diagnostics segments, plus its AI partnership with DeepHealth, are driving global medical innovation.

GE Healthcare under federal securities investigation after Q1 2026 earnings dip, CFO exit, and PDx recall – learn how these issues threaten investor trust and legal risks.

GE Healthcare’s 2026 snapshot: 4‑segment portfolio, AI partnership, and a $29B market cap—why investors see growth amid tech‑driven patient care.

GEHC’s recent institutional sell‑offs, EU consortium ties, and AI‑driven cardiac imaging push the company toward higher valuations and market leadership.

GE HealthCare expands its global reach with a 300‑CT scanner roll‑out in Indonesia and a 2030 sales extension with Vaso, boosting diagnostics and revenue.

GE Healthcare’s $1.25 billion debt and new Mayo partnership aim to boost financial health and pioneer personalized radiation therapy, but market skeptics question if these moves will translate into revenue growth.

GE Healthcare unveils its next‑generation SIGNA MRI scanners at RSNA 2025, spotlighting faster scans, patient comfort, and greener design—ready for FDA clearance and mid‑2026 launch.

GE Healthcare’s latest stock price, market cap, P/E and strategic focus reveal a cautious yet promising outlook for investors in the evolving health‑care sector.